Key Takeaways ANI Pharmaceuticals is scheduled to report Q3 results on Nov. 7 before market open.Increasing Cortrophin Gel momentum and new rare disease drugs may drive top-line strength.ANIP raised full-year 2025 revenue guidance to $818-$843M based on strong first-half results.We expect ANI Pharmaceuticals (ANIP) to surpass expectations when it reports third-quarter 2025 results on Nov. 7, before market open. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $211.3 millio ...